Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Mar 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-03-05

Reporting Person: Grossi Federico (CHIEF MEDICAL OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-05	Common Stock	M	5000	$3.20	Acquired	62814	Direct
2021-03-05	Common Stock	S	5000	$48.615	Disposed	57814	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-05	Stock Option (Right to Buy)	$3.20	M	5000	Disposed	2024-12-12	Common Stock (5000)	Direct

Footnotes

F1: This option was granted on December 12, 2014 and is fully vested.